Senesco Technologies Inc., of Bridgewater, N.J., said the Data Review Committee (DRC) for its SNS01-T trial in multiple myeloma and non-Hodgkin's B-cell lymphoma approved initiating cohort 3 and escalating the SNS01-T dose level fourfold to 0.2 mg/Kg

Liquidia Technologies Inc., of Research Triangle Park, N.C., said it intends to form a new ophthalmology-focused company

Emisphere Technologies Inc., of Roseland, N.J., said it has agreed with Novo Nordisk A/S, of Bagsvaerd, Denmark, to amend their development and license agreement to develop and commercialize oral formulations of Novo Nordisk's GLP-1 receptor agonists, which have the potential of treating Type II diabetes, using the company's Eligen technology

Pfizer also obtained a license to an in vivo rat-based human antibody production system developed by Open Monoclonal Technologies Inc. (OMT), of Palo Alto, Calif

Advanced Cell Technology Inc., of Marlborough, Mass., said the first subject in the third dosage cohort was injected with 150,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells in its European Phase I trial for Stargardt's macular dystrophy (SMD

Pfizer also obtained a license to an in vivo rat-based human antibody production system developed by Open Monoclonal Technologies Inc. (OMT), of Palo Alto, Calif

Senesco Technologies Inc., of Bridgewater, N.J., completed the second cohort of its Phase Ib/IIa trial of SNS01-T. Two multiple myeloma patients and one diffuse large B-cell lymphoma patient have completed the study

Total Value in 2013: $4,303M* Number of Deals in 2013: 68 Company (Location) Company (Location) Value (M) Type/Product Area Terms/Details Date DECEMBER AIMM Therapeutics NV (Amsterdam, the Netherlands) Cosmo Pharmaceuticals SpA (Milan, Italy) ND Strategic partnership to develop oral diagnostic and therapeutic antibodies for gastrointestinal diseases including colon carcinoma Cosmo will formulate human monoclonal antibodies generated by AIMM in an extended-release form exploiting its MMX

Advanced Cell Technology Inc., of Marlborough, Mass., treated the first patient in patient cohort 2a of its Phase I trials, consisting of patients with better vision, in its U.S

completed a 112-day follow-up period in a trial in 40 patients, and the company plans to submit a 510k application 3/15/13 OphthaliX Inc. (unit of Can-Fite BioPharma Ltd.; Petach Tikvah, Israel) CF101 A3 adenosine receptor agonist Dry eye syndrome Finished enrolling a 236-patient Phase III trial 3/19/13 Palatin Technologies Inc. (Cranbury, N.J.) Bremelano-tide A first-in-class melanocortin agonist and a synthetic peptide analogue of the naturally occurring hormone alpha-MSH Hypoactive sexual

biOasis Technologies Inc., of Vancouver, British Columbia, said BT2111, a brain-penetrating conjugate of trastuzumab (Herceptin, Roche AG) and its Transcend vector designed to treat brain metatastsis of HER2-positive tumors, has moved into the next stage of preclinical development...Critical Outcome Technologies Inc., of London, Ontario, completed a detailed analysis of preclinical data from its acute myelogenous leukemia (AML) program and will move three of the six CHEMSAS identified into animal

Advanced Cell Technology Inc., of Santa Monica, Calif., treated patients in a third cohort of each of its two Phase I trials of human embryonic stem cell-(hESC) derived retinal pigment epithelial cells for macular degeneration

Advanced Cell Technology Inc., of Santa Monica, Calif., said an independent data and safety monitoring board authorized the firm to move forward with enrollment and treatment of patients in the next cohort of each of its three ongoing trials of human embryonic stem cell-derived retinal pigment epithelial cells for eye diseases

AmVac AG, of Zug, Switzerland, disclosed new preclinical data on its vaccine candidate AMV602 for the prevention of infections caused by respiratory syncytial virus (RSV). Last fall, the company selected the candidate as the most promising for further development among a range of potential leads. In preclinical studies, researchers at the University of Siena, Italy, have confirmed the candidate's excellent safety and efficacy, showing that even reduced doses of AMV602 trigger effective immune

WuXi PharmaTech Inc., of Shanghai, China, closed a second agreement with Open Monoclonal Technology Inc., of Palo Alto, Calif., to expand WuXi's use of OMT's OmniRat and OmniMouse technologies to augment development and commercialization opportunities for WuXi's clients

Palatin Technologies Inc., of Cranbury, N.J., said bremelanotide 1.25-mg and 1.75-mg doses significantly increased sexual arousal, sexual desire and the number of sexually satisfying events, and decreased associated distress in premenopausal women with female sexual dysfunction

That drug, partnered with Emisphere Technologies Inc., showed small numerical improvements in reduction of fractures in Phase III testing in 2011, but data fell short of statistical significance, prompting the Swiss big pharma firm to opt out of further development. (See BioWorld Today, Nov. 15, 2011.) Philadelphia-based Tarsa, which is anticipating a new drug application this year, has said it likely will aim Ostora initially at patients with mild to moderate disease who cannot tolerate

Technologies Inc. (Vancouver, British Columbia) UCB SA (Brussels, Belgium) ND Deal to evaluate the application of biOasis' technology for drug delivery to the brain biOasis will carry out studies of the technology as it relates to UCB's central nervous system compounds 12/4/12 Biogen Idec Inc. (Weston, Mass.) Isis Pharmaceuticals Inc. (Carlsbad, Calif.) $200 Partnership to discover and develop antisense drugs for several undisclosed targets in the area of neurological and neuromuscular disorders

Technology Inc. (Marlborough, Mass.) Stem cells Human embryonic stem cell-derived retinal pigment epithelial cells and visual acuity gain Stargardt's macular dystrophy and dry age-related macular degeneration Phase I/II trial showed evidence of engraftment of the cells and visual acuity gain 1/9/13 La Jolla Pharmaceutical Co. (San Diego) GCS-100 Carbohydrate molecule Chronic kidney disease Administered the first dose for its Phase I/II trial 1/29/13 Proteonomix Inc. (Paramus, N.J.) UMK-121 End